Miura D S, Wynn J, Keefe D, Laux B, Somberg J C
Am Heart J. 1987 Jan;113(1):65-9. doi: 10.1016/0002-8703(87)90010-x.
The antiarrhythmic properties of indecainide were studied in 15 patients with a history of a cardiac arrest or ventricular tachycardia. Programmed electrical stimulation studies were performed in nine men and six women with a mean age of 68 +/- 2 years and a mean left ventricular ejection fraction of 41 +/- 4%. All patients had inducible ventricular tachycardia by programmed electrical stimulation while off all antiarrhythmic therapy. Patients were then tested on procainamide, 1000 mg, administered intravenously, and ventricular tachycardia could be provoked in 10 of 15 patients. Indecainide was given intravenously, 1 mg/kg. Indecainide did not significantly change the baseline heart rate, blood pressure, and QTc interval from control values. The PR and QRS intervals were significantly prolonged. Twelve of 15 patients were still inducible for ventricular tachycardia on indecainide. Procainamide protected 5 of 15 patients against ventricular tachycardia induction. In patients still inducible on indecainide therapy, the ventricular tachycardia rate was significantly slowed, from 281 bpm to 224 bpm on indecainide and to 215 bpm on procainamide. The effects of this new class IC antiarrhythmic agent appears similar to procainamide in patients with serious life-threatening tachyarrhythmias.
对15例有心脏骤停或室性心动过速病史的患者研究了茚卡尼的抗心律失常特性。对9名男性和6名女性进行了程序电刺激研究，他们的平均年龄为68±2岁，平均左心室射血分数为41±4%。所有患者在停用所有抗心律失常治疗时，通过程序电刺激均可诱发室性心动过速。然后对患者静脉注射1000mg普鲁卡因胺进行测试，15例患者中有10例可诱发室性心动过速。静脉注射茚卡尼，剂量为1mg/kg。茚卡尼与对照值相比，未显著改变基础心率、血压和QTc间期。PR和QRS间期显著延长。15例患者中有12例在使用茚卡尼时仍可诱发室性心动过速。普鲁卡因胺使15例患者中有5例免受室性心动过速的诱发。在茚卡尼治疗下仍可诱发室性心动过速的患者中，室性心动过速的速率显著减慢，使用茚卡尼时从281次/分钟降至224次/分钟，使用普鲁卡因胺时降至215次/分钟。在患有严重危及生命的快速心律失常的患者中，这种新型IC类抗心律失常药物的作用似乎与普鲁卡因胺相似。
